Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07125352

Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) stands as one of the leading causes of mortality worldwide. Acute exacerbations of COPD (AECOPD) lead to rapid respiratory function decline and worsened disease status. Despite recent studies, the ability of the neutrophil-to-lymphocyte ratio (NLR) to predict outcomes in patients with COPD remains controversial. It remains controversial whether NLR can predict clinical outcomes in hospitalized patients with AECOPD. Therefore, this study was conducted to investigate the predictive value of NLR for severity, adverse outcomes in hospitalized patients with AECOPD, and predicting treatment response in patients with AECOPD

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain Shams University

Cairo, Abbasyea, 02, Egypt

Location status: Recruiting

Location contact

Fatma S Ebeid

CONTACT

[email protected]

01095569596

About this study

Chronic obstructive pulmonary disease (COPD) stands as one of the leading causes of mortality worldwide, posing an increasing economic burden. Acute exacerbations of COPD (AECOPD) are defined as acute deterioration of respiratory symptoms requiring additional treatment, leading to rapid respiratory function decline, diminished quality of life, and worsened disease status. Neutrophils are the most common type of white blood cells (WBC) and participate in multiple inflammatory and immune processes through phagocytosis and cytokine release. Lymphocytes play a crucial role as coordinators of the inflammatory and immune processes in various physiological mechanisms. The neutrophil-to-lymphocyte ratio (NLR) is calculated by dividing the number of neutrophils by the number of lymphocytes in the peripheral blood test, reflecting an increase in neutrophils and a secondary decrease in lymphocyte count during the inflammatory response. The NLR is considered a biological marker reflecting the inflammatory condition and is increasingly recognized in various disorders such as pneumonia, malignant, coronary artery disease, or hematological disorders.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 and above, Patients who will be admitted at the Chest department, Ain-Shams University Hospitals, diagnosed with AECOPD based on the Global Initiative for Chronic Obstructive Lung Disease 2024 criteria

Exclusion criteria

  • Patients who refused treatment.
  • COPD patients with Malignancy, hematological disorders

Treatment and study plan

neutrophil lymphocyte ratio in COPD patients

Other

Neutrophil lymphocyte ratio in determining severity and prognosis in exacerbation of COPD patients

Primary outcomes

  1. The ratio of neutrophils to lymphocytes in (%) in the CBC

    Time frame: baseline

    investigate the relation between this % ratio and severity of symptoms and adverse hospitalization outcomes in hospitalized patients with AECOPD

Secondary outcomes

  1. The ratio of neutrophils to lymphocytes in (%) in the CBC

    Time frame: 3 months

    • investigate the relation between this % ratio and spirometric indices (FEV1, FVC) as percent predicted in hospitalized patients with AECOPD in their follow up

Study contacts

Contact information is provided by the study sponsor or research team.

Hieba G Ezzelregal, MD

CONTACT

[email protected]

01002041611

mona A alhady, MD

CONTACT

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Marker of Severity and Prognosis

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Aug 15, 2025
Registry last updated
Aug 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.